Journal article
Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis
Abstract
BACKGROUND: In cystic fibrosis (CF), omalizumab has been used for difficult-to-treat asthma and allergic bronchopulmonary aspergillosis (ABPA) but safety and efficacy data are limited for this population.
METHODS: We assessed patients receiving omalizumab for asthma or ABPA in the Toronto adult CF center between 2005 and 2017. We evaluated treatment safety and efficacy by analyzing changes in FEV1% predicted (FEV1pp) max value, slope and …
Authors
Koutsokera A; Corriveau S; Sykes J; Coriati A; Cortes D; Vadas P; Chaparro C; McIntyre K; Tullis E; Stephenson AL
Journal
Journal of Cystic Fibrosis, Vol. 19, No. 1, pp. 119–124
Publisher
Elsevier
Publication Date
January 2020
DOI
10.1016/j.jcf.2019.07.011
ISSN
1569-1993